Tiny Health Raised $33 Million in Series B Funding
The Austin-based biotech startup secured capital to expand its microbiome research and B2B health platform.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Is now a good time to invest in personalized microbiome or health testing for your household?
Austin-based Tiny Health has secured $33 million in an oversubscribed Series B funding round led by B Capital. This latest investment brings the company's total funding to $46 million.
Why it matters
The company intends to use the capital to advance clinical research, scale its B2B platform, and expand education for healthcare practitioners. The funding supports a broader mission to make the gut microbiome measurable, accessible, and actionable.
Tiny Health utilizes an in-house bioinformatics pipeline and AI platform trained on a proprietary dataset of 200,000 microbiome profiles. Its technology identifies over 120,000 genomes through shotgun metagenomic sequencing.
The players
Tiny Health
This Austin-based biotechnology firm specializes in gut and vaginal microbiome testing.
B Capital
This global multi-stage investment firm led the company's latest funding round.
The details
Tiny Health simultaneously launched a $5 million Microbiome Research Program to further its clinical investigations. The startup currently serves 200,000 customers and has seen its B2B platform, Powered by Tiny, grow fourfold over the past year.
Timeline
Tiny Health was founded in 2020.
The company launched its testing platform in 2022.
A 2025 study showed microbiome interventions reduced infant eczema odds by 83%.
Tiny Health announced its $33 million Series B funding on September 29, 2026.
The Tech Race
The company’s growth follows a pattern set by increasing institutional interest in the clinical application of gut health data. This investment underscores the ongoing race to commercialize microbiome diagnostics and move beyond simple data collection into actionable clinical interventions.
Customers may gain access to expanded diagnostic capabilities as the company scales its platform and increases its practitioner network. The research advancements could eventually lead to new, scientifically validated interventions for chronic conditions.
The takeaway
The firm’s focus on large-scale data and clinical validation highlights a shift toward evidence-based microbiome management. Patients should watch for emerging clinical studies as the company moves to translate its massive dataset into broader medical applications.
Further reading
Learn more about the latest innovations in the field by visiting our Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Is now a good time to invest in personalized microbiome or health testing for your household?
